Phase III research

Lumacaftor-ivacaftor combination improves lung function in cystic fibrosis

Combination therapy with two drugs that target the most common genetic cause of cystic fibrosis (CF) has been found to improve lung function in patients with the disease.…

Drug development: the journey of a medicine from lab to shelf

Before a drug is deemed suitable for patients, it has to go through rigorous testing and cost-effectiveness analyses.…

ResearchKit: a clever tool to gather clinical data

New software from Apple makes it easy for iPhone users to contribute to medical research but scientists warn there may be pitfalls.…

Systematic review suggests mortality benefits of new cholesterol lowering biologics

Monoclonal antibodies designed to lower cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) are effective and associated with few major side effects.…

David Reddy: delivery of new anti-malaria drugs to developing countries is vital in fight against the disease

David Reddy, Medicines for Malaria Venture’s chief executive officer, discusses developments in the fight against the disease ahead of World Malaria Day on 25 April.…

Nine-component HPV vaccine aims to prevent 90% of cervical cancers

Researchers have developed a new nine-component vaccine against human papillomavirus which they believe could increase overall protection against cervical cancers to 90%.…

Carfilzomib gives survival benefits to patients with relapsed multiple myeloma

Adding the proteasome inhibitor carfilzomib to lenalidomide plus dexamethasone, the standard treatment for patients with relapsed multiple myeloma, significantly improves outcomes.…

UK government to review access to new medicines and diagnostics

Plans may include integrating the health service with life sciences research to bring innovations to patients faster.…

Immune checkpoint inhibitors bring new hope to cancer patients

PD-1 and PD-L1 inhibitors induce a higher response rate across a wider range of tumours than other immunotherapies.…

Forces driving the evolution of biologics into biosimilars and biobetters

As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…